Devices based on semi-quantitative “sandwich” lateral flow immunoassay and methods of using the devices are provided to determine the presence and estimate the quantity of Flt-1 protein found in the plasma, serum, whole blood, saliva, urine or another bodily fluid of pregnant women in order to predict or screen for the risk of preeclampsia in pregnant women. Assays based on the devices are also provided.

Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.

[Problem ] Provided is a means for detecting and quantifying a biological substance of interest with an improved accuracy by inhibiting non-specific adsorption of fluorescent nanoparticles and thereby reducing the background noise in immunostaining with fluorescent nanoparticles. [Means for Solution] Immunostaining is carried out upon diluting fluorescent nanoparticles with a fluorescent nanoparticle diluent which contains 1 to 5% (W/W) of a protein having a molecular weight of 40,000 or higher (e,g., BSA) and 1 to 3% (W/W) of a protein having a molecular weight of less than 40,000 (eg ., casein) and, when casein is used as a low-molecular-weight protein, it is preferred that the κ-casein content in the casein is 10% (W/W) or less and the ratio of α-casein and β-casein (α-casein:β-casein) contained in the casein is 40:60 to 60:40 ( taking the total amount of α-casein and β-casein as 100).

An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.

A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.

Provided herein a method for enhanced assessment of breast cancer in a subject including identification of circulating breast cancer cells in a biological sample and single-cell, whole-genome sequencing of the identified circulating breast cancer cells. Optionally, cell-free tumor DNA is further assessed from the same biological sample or a parallel sample. Also provided are methods of treating a subject with breast cancer using the enhanced assessment to select one or more anti-cancer agents for administering to the subject.

Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.

A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.

The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Hist1h2bc, Egrl, BX842664.2/Hist 1h3c, Dhfr, Fgfr2, AC115880.11, Mmp10, Vsnll (optional), CU459186.17, El 30203 B14Rik, Cspg4, C1qtnf1, Foxp2, and Ptpre.

Provided is a method for screening a compound that can specifically suppress the formation of caveolae of cancer cells and can inhibit the activity of various RTKs using a single compound all at once. A method for screening a compound specifically suppressing the formation of caveolae of cancer cells wherein the screening method includes a step for bringing a test compound into contact with a system capable of detecting suppression of the binding of Cavin-1 and CAV1 and a step for selecting a compound having activity to suppress the binding of Cavin-1 and CAV1.